Updated on 15 May 2012
Besides getting government support, Inno Biologics has signed a cooperation agreement with Boehringer Ingelheim, a top pharma company. Through the partnership, it offers its clients access to Boehringer Ingelheim's enhanced manufacturing technology platform, protocols and support and well-established bioprocessing services for various stages of process development and biomanufacturing. Inno Biologics will have non-exclusive access to Boehringer Ingelheim's comprehensive manufacturing technology platform for cell culture products, including its state-of-the art BI HEX cell expression system. This strategic partnership provides Inno Biologics with the advantages of offering a complete range of services from the clinical stages up to the commercialization with a seamless transfer of technology.
Inno Biologics is involved in many projects with clients in developing and producing monoclonal antibodies for both therapeutic and diagnostic application. The company has secured partnership agreements with several international firms. Current ventures include a deal with an Indian drug developer, Avesta Biotherapeutics & Research to produce biopharmaceuticals over a five-year contract term. The contract signed with the Indian firm signifies its agile strategy to gain international recognition for Inno Biologics, and this will motivate the company to strive forward, and actively pursue its mission to be the world leading business organization in providing biopharmaceutical development and services.
Inno Biologics has grown in the last couple of years and emerged as a medium scale global CMO specializing in mammalian cell culture manufacturing of biopharmaceuticals for phase I-II clinical trials. Right now, it employs 95 people that includes 35 scientists and 17 engineers. With exclusive partnerships in place and more in negotiation, Inno Biologics' access to high standard of technology is set as an important differentiator from other competitors.
As a CMO for clinical materials, Inno Biologics aims to bridge the gap between R&D endeavors and commercialization activities. The company provides an array of R&D services including cell line development and engineering, hybridoma technology and antibody production, mammalian cell culture medium and development, call banking, protein expression and verification, process flow modeling, biotech project management and clinical material production (cGMP environment).
With the research funding from MOSTI, Malaysia, Inno Biologics is focused on development of therapeutic/diagnostic antibodies against colorectal cancer markers. The company has acquired through licensing two murine antibodies from Cuba's Center for Molecular Immunology (CIM). Using a proprietary technology from CIM, the Inno has successfully humanized the antibodies and in the process conducting immunogenicity and toxicology studies in animal models.